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Prostate cancer treatment has evolved
through the varying eras of therapy from
one of predominantly hormonal agents
without much effective cytotoxic ther-
apy until the use of docetaxel was found
to improve overall survival in the piv-
otal TAX-327 (1) and SWOG 99-16 tri-
als (2). While efforts to search for the
appropriate docetaxel partner has yielded
disappointing results with multiple Phase
III trials showing negative results, further
hormonal manipulation steadily gained
ground upon discovery of persistent hor-
monal signaling with the use of novel
androgen-biosynthesis inhibitors and anti-
androgens. However, resistance to these
agents is ultimately inevitable. Increased
understanding of these resistance mech-
anisms may help re-channeling efforts
toward better refinement and improve-
ment of drug therapies.
Prostate cancer remains the second
leading cause of death in the United States.
While treatment for early-stage low-risk
prostate cancer has been largely contro-
versial with the advent of the prostate
specific antigen (PSA) screening contro-
versy, treatment for metastatic castration-
resistant prostate cancer (mCRPC) has
evolved with great strides in the past
decade, though remains incurable to this
day. Docetaxel as a treatment for mCRPC
brought about improvement in overall sur-
vival (1). To date, no appropriate doc-
etaxel partner has been found to be ben-
eficial. However, the utility of androgen
targeted signaling quickly gained ground
with the discovery of the relevance of
androgen receptor (AR) targeting long
after failure from androgen deprivation
therapy (3). This brought about the dis-
covery and subsequent approval of both
abiraterone acetate (4, 5) and enzalu-
tamide (6, 7) in both the post-docetaxel
and pre-docetaxel space. While target-
ing androgen-signaling to date makes for
one of the most attractive approaches
in mCRPC therapy, several challenges
remain.
The AR is a 110-kDa steroid recep-
tor encoded by the gene located in Xq11-
12 in the same family of nuclear hor-
mone receptors as the estrogen, proges-
terone, and glucocorticoid receptors (8).
The AR functions as a “lineage oncogene”
of which prostate tumors become habitu-
ally addicted to (9). Conversely, several AR-
pathway genes are down-regulated upon
progression from a low-grade to high-
grade prostate cancer or in the develop-
ment of metastases (10). Despite targeting
the AR pathway using more contemporary
drugs with abiraterone or enzalutamide, it
is now increasingly recognized that resis-
tance patterns are born at the cellular level,
with ligand independent AR activation, AR
mutation, intratumoral androgen synthe-
sis, increased AR mRNA expression, and
AR maintenance by heat shock proteins
and AR structural alterations including
acquisition of splice variants all playing a
role in resistance (11). Given the inevitable
notion of resistance, efforts toward not just
sequencing, but combining these agents
offer exciting insights and opportunities
for treatment. For instance, TOK-001,
also known as galeterone, is a rationally
designed compound that has triple mech-
anism of action that includes inhibition of
CYP17A1 enzyme thereby blocking andro-
gen synthesis, with preferential lyase over
hydroxylase inhibition, AR inhibition by
antagonizing testosterone binding to the
AR, which prevents binding of synthetic
androgens to both mutant and wild-type
AR, and finally, decreasing the amount of
AR through degradation of the AR pro-
tein. These unique mechanisms of action
are thought to be a possible promising
agent for the treatment of CRPC (12).
Thus, far, early Phase I testing (ARMOR 1)
demonstrating a minimal side effect pro-
file has led to a Phase II trial (ARMOR
2) evaluating efficacy by means of PSA
response (NCT01709734). While TOK-001
and other promising drugs such as ARN-
509 are in the pipeline (13), there remains
a concern of whether the clinical trial end-
point that we are accustomed to that of
overall survival is the most appropriate
endpoint. To illustrate this point, results of
a lyase inhibitor TAK-700 or orteronel have
been presented in both the post-docetaxel
and pre-docetaxel setting. While the eli-
gibility criteria and study design appears
comparable to contemporary clinical tri-
als such as the COU-AA-301 and COU-
AA-302 as well as AFFIRM and PREVAIL
trials with abiraterone and enzalutamide,
respectively, the TAK-700 trials ELM-PC5
and ELM-PC4 were disappointingly nega-
tive. This raises a concern since this drug,
along with a multitude of other drugs, may
not necessarily be clinically inferior, but
increasingly difficult to prove superiority
or even equivalency given the landscape
of drugs currently approved that has been
shown to improve overall survival.
Addressing the issue of resistance is of
relevant importance given the notion that
all CRPC tumors will fail treatment even-
tually. Provocative findings show gain-of-
function mutation in 3β-hydroxysteroid
dehydrogenase type 1 (3βHSD1) enzyme
that renders an alternative pathway to
resistance by inhibition of degradation
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and therefore provides a rapid route
of conversion of an adrenal-derived
dehydroepiandrosterone (DHEA) to the
more potent androgen dihydrotestosterone
(DHT), which can activate the AR (14).
Increasing observation also abounds with
regard to cross-resistance with novel
androgen-signaling inhibitors where less
than optimal responses are seen with enza-
lutamide post-abiraterone (15, 16) and
vice-versa (response with abiraterone post-
enzalutamide) (17). This phenomenon of
cross-resistance may also be seen with the
use of taxanes (18) with increasing recogni-
tion that taxanes inhibit AR translocation
with resultant inferior responses to doc-
etaxel after abiraterone initiation (19). The
concurrent use of glucocorticoids has also
been touted as a possible mechanism of
resistance, especially in later stages of dis-
ease although this has been widely debated
(20). Identification of AR splice variants as
a mechanism of resistance may better pre-
dict the upfront resistance to the androgen-
signaling inhibitors, which may guide ther-
apy as recently shown in lack of response
to either abiraterone or enzalutamide in
tumors harboring the AR-V7 splice variant
(21). In addition, better characterization of
genetic and chromosomal rearrangements
lends insights to potential targeting. For
instance, one of the most prevalent onco-
genes expressed in prostate cancer is that of
ETS-related gene 1 (ERG) (22) and mem-
bers of the ETS family of transcription fac-
tors (ERB, ETV1, ETV4) are placed under
the control of an androgen-regulated pro-
moter that occurs in the transmembrane
protease, serine 2 (TMPRSS2), resulting in
a gene fusion TMPRSS2-ERG that occurs
in up to 50% of localized or metastatic
prostate cancer. This may be relevant with
addressing not only progression but also
averting resistance or determining drug
sequence patterns since response to abi-
raterone seem to be better in those who
harbor the gene fusion (23, 24). Another
interesting observation is the relationship
between this gene fusion with PTEN. An
invasive prostate cancer phenotype is pro-
moted in phosphoinositide 3-kinase (PI3-
kinase) activation (25) or PTEN loss (26).
The cross-talk between PI3-kinase and
androgen-signaling (27) offers a pharma-
cologic opportunity to achieve dual inhibi-
tion of compensatory pathways to avert the
reciprocal feedback loop. Similar reciprocal
relationship has been observed with andro-
gen repression and c-met signaling with
resultant epithelial–mesenchymal transi-
tion (EMT) and stem-cell like phenotype.
In addition to the aforementioned genomic
aberrations, deletion in NKX3.1, amplifi-
cation in C-Myc, deletion of p53, deletion
in CHD1, RB1, FOXA1, SPOP, and the
HSP70/HSP90 chaperone complex have all
been described (28, 29). Recently, a novel
approach to targeting the bromodomain
chromatin-binding protein BRD4, which
interacts with the N-terminal domain of
the AR using a small molecule JQ1, was
reported (30). While similar to enzalu-
tamide in its ability to inhibit AR recruit-
ment, it improves upon enzalutamide’s
action in its downstream AR binding, tran-
scriptional regulation, and induction of
TMPRSS2-ERG gene oncogenic function.
In summary, much progress has been
made in the past decade alone in mCRPC
therapy, but a lot remains to be done to
further elucidate mechanisms of resistance
and to circumvent these resistance mech-
anisms. The AR remains to be a versatile
foe from progression of localized prostate
cancer to advanced and metastatic prostate
cancer and beyond castration-resistance.
Provocative findings of transcriptional reg-
ulatory pathways and methods of inhibit-
ing them will usher in an exciting era of
targeting the AR in CRPC.
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